The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1
Open accessAbstract
Purpose: COVID-19-associated rhino-orbital-cerebral mucormycosis (ROCM) has reached epidemic proportion during India’s second wave of COVID-19 pandemic, with several risk factors being implicated in its pathogenesis. This study aimed to determine the patient demographics, risk factors including comorbidities, and medications used to treat COVID-19, presenting symptoms and signs, and the outcome of management. Methods: This was a retrospective, observational study of patients with COVID-19-associated ROCM managed or co-managed by ophthalmologists in India from January 1, 2020 to May 26, 2021. Results: Of the 2826 patients, the states of Gujarat (22%) and Maharashtra (21%) reported the highest number of ROCM. The mean age of patients was 51.9 years with a male preponderance (71%). While 57% of the patients needed oxygen support for COVID-19 infection, 87% of the patients were treated with corticosteroids, (21% for > 10 days). Diabetes mellitus (DM) was present in 78% of all patients. Most of the cases showed onset of symptoms of ROCM between day 10 and day 15 from the diagnosis of COVID-19, 56% developed within 14 days after COVID-19 diagnosis, while 44% had delayed onset beyond 14 days. Orbit was involved in 72% of patients, with stage 3c forming the bulk (27%). Overall treatment included intravenous amphotericin B in 73%, functional endoscopic sinus surgery (FESS)/paranasal sinus (PNS) debridement in 56%, orbital exenteration in 15%, and both FESS/PNS debridement and orbital exenteration in 17%. Intraorbital injection of amphotericin B was administered in 22%. At final follow-up, mortality was 14%. Disease stage >3b had poorer prognosis. Paranasal sinus debridement and orbital exenteration reduced the mortality rate from 52% to 39% in patients with stage 4 disease with intracranial extension (p < 0.05). Conclusion: Corticosteroids and DM are the most important predisposing factors in the development of COVID-19-associated ROCM. COVID-19 patients must be followed up beyond recovery. Awareness of red flag symptoms and signs, high index of clinical suspicion, prompt diagnosis, and early initiation of treatment with amphotericin B, aggressive surgical debridement of the PNS, and orbital exenteration, where indicated, are essential for successful outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Rawson, T. M., Moore, L. S. P., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., Satta, G., Cooke, G., & Holmes, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa530 · Cited by 1,662
Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India
Singh, A. K., Singh, R., Joshi, S. R., & Misra, A. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.05.019 · Cited by 1,102
Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes
Yang, J.-K., Lin, S.-S., Ji, X.-J., & Guo, L.-M. (2010) · Acta Diabetologica · doi:10.1007/s00592-009-0109-4 · Cited by 1,084
Jeong, W., Keighley, C., Wolfe, R., Lee, W. L., Slavin, M. A., Kong, D. C. M., & Chen, S. C.-A. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.07.011 · Cited by 1,082
Global Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 704
Epidemiology and Diagnosis of Mucormycosis: An Update
Skiada, A., Pavleas, I., & Drogari-Apiranthitou, M. (2020) · Journal of Fungi · doi:10.3390/jof6040265 · Cited by 687
Cited by
COVID-19-associated fungal infections
Hoenigl, M., Seidel, D., Sprute, R., Cunha, C., Oliverio, M., Goldman, G. H., Ibrahim, A. S., & Carvalho, A. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01172-2 · Cited by 482
Let’s talk about sex characteristics—as a risk factor for invasive fungal diseases.
Egger, M., Hoenigl, M., Thompson, G. R., Carvalho, A., & Jenks, J. D. (2022) · Mycoses · doi:10.1111/myc.13449 · Cited by 82
Metadata
- Authors
- Sen, M., Honavar, S. G., Bansal, R., Sengupta, S., Rao, R., Kim, U., Sharma, M., Sachdev, M., Grover, A. K., Surve, A., Budharapu, A., Ramadhin, A. K., Tripathi, A. K., Gupta, A., Bhargava, A., Sahu, A., Khairnar, A., Kochar, A., Madhavani, A., Shrivastava, A. K., Desai, A. K., Paul, A., Ayyar, A., Bhatnagar, A., Singhal, A., Nikose, A. S., Bhargava, A., Tenagi, A. L., Kamble, A., Nariani, A., Patel, B., Kashyap, B., Dhawan, B., Vohra, B., Mandke, C., Thrishulamurthy, C., Sambare, C., Sarkar, D., Mankad, D. S., Maheshwari, D., Lalwani, D., Kanani, D., Patel, D., Manjandavida, F. P., Godhani, F., Agarwal, G. A., Ravulaparthi, G., Shilpa, G. V., Deshpande, G., Thakkar, H., Shah, H., Ojha, H. R., Jani, H., Gontia, J., Mishrikotkar, J. P., Likhari, K., Prajapati, K., Porwal, K., Koka, K., Dharawat, K. S., Ramamurthy, L. B., Bhattacharyya, M., Saini, M., Christy, M. C., Das, M., Hada, M., Panchal, M., Pandharpurkar, M., Ali, M. O., Porwal, M., Gangashetappa, N., Mehrotra, N., Bijlani, N., Gajendragadkar, N., Nagarkar, N. M., Modi, P., Rewri, P., Sao, P., Patil, P. S., Giri, P., Kapadia, P., Yadav, P., Bhagat, P., Parekh, R., Dyaberi, R., Chauhan, R. S., Kaur, R., Duvesh, R. K., Murthy, R., Dandu, R. V., Kathiara, R., Beri, R., Pandit, R., Rani, R. H., Gupta, R., Pherwani, R., Sapkal, R., Mehta, R., Tadepalli, S., Fatima, S., Karmarkar, S., Patil, S. S., Shah, S., Shah, S., Shah, S., Dubey, S., Gandhi, S., Kanakpur, S., Mohan, S., Bhomaj, S., Kerkar, S., Jariwala, S., Sahu, S., Tara, S., Maru, S. K., Jhavar, S., Sharma, S., Gupta, S., Kumari, S., Das, S., Menon, S., Burkule, S., Nisar, S. P., Kaliaperumal, S., Rao, S., Pakrasi, S., Rathod, S., Biradar, S. G., Kumar, S., Dutt, S., Bansal, S., Ravani, S. A., Lohiya, S., Rizvi, S. W. A., Gokhale, T., Lahane, T. P., Vukkadala, T., Grover, T., Bhesaniya, T., Chawla, U., Singh, U., Une, V. L., Nandedkar, V., Subramaniam, V., Eswaran, V., Chaudhry, V. N., Rangarajan, V., Dehane, V., Sahasrabudhe, V. M., Sowjanya, Y., Tupkary, Y., Phadke, Y., & and the members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group
- Venue
- Indian Journal of Ophthalmology
- Published
- 2021-06-18
- Volume
- 69
- Issue
- 7
- Pages
- 1670-1692
- ISSN
- 0301-4738 (ISSN-L)
- 1998-3689
- OpenAlex
- W3176054457
- Cited by
- 418
- References
- 44
- FWCI
- 27.10
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. https://app.cochat.ai/papers/10.4103/ijo.ijo_1565_21
- The paper
- Sen, M., Honavar, S. G., Bansal, R., Sengupta, S., Rao, R., Kim, U., Sharma, M., Sachdev, M., Grover, A. K., Surve, A., Budharapu, A., Ramadhin, A. K., Tripathi, A. K., Gupta, A., Bhargava, A., Sahu, A., Khairnar, A., Kochar, A., Madhavani, A., . . . and the members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group. (2021). Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_1565_21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.